McKesson Corporation announced it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032. The Irving, Texas-based company said the extension builds on a relationship of more than 25 years, according to chair and chief executive officer Brian Tyler. McKesson is reaffirming its fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00 and its long-term adjusted EPS growth rate of 13% to 16%. Further updates will be provided during the company's second quarter fiscal 2027 earnings call on November 4, 2026. The company cautioned that the deal remains an agreement in principle and that risks include possible delays in signing a definitive contract, a failure to sign one, or not realizing all expected financial and operational benefits.
McKesson CorporationMcKesson reaffirms fiscal 2027 adjusted EPS guidance of $44.20-$45.00 and long-term EPS growth of 13%-16%.
CVS Health CorpCVS Health extends its pharmaceutical distribution partnership with McKesson through June 2032, securing its drug supply.
